# Pharmacokinetics and Pharmacodynamics of Emicizumab in Hemophilia A

## Emicizumab exhibits predictable, dose-proportional pharmacokinetics

Emicizumab demonstrates dose-proportional, predictable pharmacokinetics across diverse hemophilia A populations, with subcutaneous administration achieving sustained trough concentrations of 42-66 µg/mL during maintenance dosing across weekly (1.5 mg/kg), every-2-weeks (3 mg/kg), and every-4-weeks (6 mg/kg) regimens. The median elimination half-life is 23-30 days, with time to steady-state of 12 weeks with loading doses and 24 weeks without.

## Abstract

## Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

## Screening

We screened in sources based on their abstracts that met these criteria:
- **Population - Hemophilia A**
- **Intervention - Emicizumab**
- **Outcome - PK/PD Data**
- **Study Population - Human Subjects**
- **Study Design**
- **Intervention Specificity**
- **Population Specificity**
- **Data Relevance**

## Results

### Characteristics of Included Studies

The review included 10 sources examining emicizumab pharmacokinetics and pharmacodynamics in hemophilia A, comprising clinical trial reports, a systematic review, and an exposure-response modeling study.

### Dosing Regimens and Administration

Emicizumab was administered subcutaneously across all studies, with various loading and maintenance regimens tested to optimize pharmacokinetic profiles.

### Pharmacokinetic Parameters

Emicizumab demonstrated predictable, dose-proportional pharmacokinetics across diverse patient populations.

#### Plasma Concentrations

Trough concentrations increased during the loading phase, reaching mean values of 52.9-63.2 µg/mL by week 5. Emicizumab concentrations were higher in infants (60-65 µg/mL) compared to older individuals.

### Pharmacodynamic Outcomes

#### FVIII-Equivalent Activity and Coagulation Parameters

- FVIII-equivalent activity levels remained above 20 U/dL 
- aPTT was normalized at subtherapeutic concentrations
- Peak thrombin generation reached above 100 nM

#### Bleeding Outcomes

Emicizumab prophylaxis demonstrated substantial efficacy in reducing bleeding rates across all studies. The proportion of patients achieving zero treated bleeds varied from 54.5% to 77.8%.

## Safety Profile

Emicizumab demonstrated a favorable safety profile across all studies, with injection site reactions being the most frequent treatment-related adverse event.

### Immunogenicity

Emicizumab demonstrated minimal immunogenicity across studies. None of the participants in the HAVEN 7 studies tested positive for anti-drug antibodies.

## Study Methodologies

The studies employed diverse methodological approaches to assess emicizumab pharmacokinetics and pharmacodynamics, ranging from Phase I dose-escalation studies to large Phase III randomized trials and sophisticated modeling analyses.